these therapies include the products of biotechnology such as recombinant proteins and antibodies (collectively termed biopharmaceuticals) as well as several older drugs produced through purification techniques such as heparins and conjugated oestrogens. Biosimilars (europe) or 'follow-on' biologics (USA) are biological products that are similar, but not identical, to an innovator product that is already marketed and whose patent has typically expired. Biosimilars cannot be considered 'generic' equivalents of innovator products as they are not necessarily clinically interchangeable and in some cases may exhibit different therapeutic effects. It is critical that physicians and pharmacists truly understand the complex factors which apply to this new and challenging area.
Biological drugs are far more complex than conventional small molecule pharmaceutical products. Whereas conventional drugs can be completely characterised on the basis of their chemical structures, biological drugs tend to be recombinant three-dimensional proteins with structural complexity and a high molecular weight. this makes them difficult to characterise. the complexity of biological drugs also emanates from the elaborate manufacturing processes involved in their production. 1 A major concern with biological drugs is immunogenicity. the guidelines call for far more rigorous testing than would be needed for a chemical generic product. these requirements include pharmaco-toxicological assessment, and pharmacokinetic, pharmacodynamic, efficacy and clinical safety studies. 4 Due to the unpredictability of the onset and incidence of immunogenicity, postmarketing surveillance is a priority with biosimilars. the european guidelines require the manufacturer to submit a comprehensive pharmacovigilance plan with a focus on monitoring immunogenicity after the product has been marketed. this plan must be established at the time of marketing approval. 4 Also, stringent quality control guidelines recommend that both innovator and biosimilar manufacturers ensure consistency in their production by performing rigorous purity and activity profiling between batches. 5 Providing clinicians with the product summary, the evaluation of the clinical data used for approval, and advice about substitution will be critical for patient care.
Biopharmaceuticals are relatively expensive compared to chemical drugs because of their complex manufacture and clinical development and the costs of handling, distribution and delivery systems. the main reason for using a biosimilar is that it is cheaper than the original product. 6 However, the potential cost-savings associated with biosimilars will be less than the savings from ordinary generics. this is due to the higher manufacturing costs, more extensive testing requirements -generally efficacy and safety have to be demonstrated separately for each of the claimed indications 7 -and the need for a postmarketing pharmacovigilance plan.
Incorporating biopharmaceuticals as therapeutic options into patient management is the new reality. Awareness of the quality, safety and efficacy issues and the differences between biosimilars and innovator products is essential for patient safety. Any decisions to substitute one biopharmaceutical with another should be made with the knowledge and prior consent of the physician. In particular, pharmacovigilance is a shared responsibility between the pharmaceutical industry, physicians, pharmacists, nurses and patients.
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